Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2008

01.03.2008 | Original Paper

Treatment Eligibility and Outcomes in Elderly Patients with Chronic Hepatitis C: Results from the VA HCV-001 Study

verfasst von: Judith I. Tsui, Sue Currie, Hui Shen, Edmund J. Bini, Norbert Brau, Teresa L. Wright, For the VA HCV-001 Study group

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives We undertook this study to determine if treatment candidacy and outcomes were similar between elderly and non-elderly patients. Methods This was a prospective cohort study that screened 4,025 patients with chronic hepatitis C for HCV antiviral treatment at 24 Veterans Affairs Medical Centers throughout the country. We used multivariable logistic regression to determine whether there was an independent association between being elderly (age > 60 vs. ≤ 60) and (1) being considered a treatment candidate by clinician, and (2) achieving sustained virologic response if treated. Results 364 of the 4,025 patients (9%) were over the age of 60. Only 25% of patients over the age of 60 were considered to be treatment candidates by the evaluating clinician, and only 10% were started on treatment. After adjustment for potential confounders, older age remained associated with a lower likelihood of being considered a treatment candidate (adjusted OR = 0.43; 95% CI: 0.30–0.61). Although based on a small sample of elderly treated patients (n = 35), being elderly did not appear to be associated with a lower likelihood of achieving SVR (adjusted OR = 1.54; 95% CI: 0.46–5.15). Conclusion Among veterans over the age of 60 with chronic hepatitis C who are referred for treatment, relatively few are considered treatment candidates and an even smaller number are ultimately treated. After adjusting for co-morbidities, age remains a strong predictor of not being a treatment candidate. In contrast, older age does not seem to adversely affect treatment outcomes and side effects.
Literatur
1.
Zurück zum Zitat Armstrong GL, Wasley A, Simard EP et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–714PubMed Armstrong GL, Wasley A, Simard EP et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705–714PubMed
2.
Zurück zum Zitat NIH Consensus Statement on Management of Hepatitis C: (2002) NIH Consens State Sci Statements 19:1–46 NIH Consensus Statement on Management of Hepatitis C: (2002) NIH Consens State Sci Statements 19:1–46
3.
Zurück zum Zitat Strader DB, Wright T, Thomas DL et al (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRef Strader DB, Wright T, Thomas DL et al (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRef
4.
Zurück zum Zitat Marcellin P, Asselah T, Boyer N (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36:S47–S56PubMedCrossRef Marcellin P, Asselah T, Boyer N (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36:S47–S56PubMedCrossRef
5.
Zurück zum Zitat Poynard T, Ratziu V, Benmanov Y et al (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47–55PubMedCrossRef Poynard T, Ratziu V, Benmanov Y et al (2000) Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 20:47–55PubMedCrossRef
7.
Zurück zum Zitat Regev A, Schiff ER (2001) Liver disease in the elderly. Gastroenterol Clin North Am 30:547–63, x–xi Regev A, Schiff ER (2001) Liver disease in the elderly. Gastroenterol Clin North Am 30:547–63, x–xi
8.
Zurück zum Zitat El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRef El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRef
9.
Zurück zum Zitat Bini EJ, Brau N, Currie S et al (2005) Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772–1779PubMedCrossRef Bini EJ, Brau N, Currie S et al (2005) Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772–1779PubMedCrossRef
10.
Zurück zum Zitat Brau N, Bini EJ, Currie S et al (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 13:242–249PubMedCrossRef Brau N, Bini EJ, Currie S et al (2006) Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 13:242–249PubMedCrossRef
11.
Zurück zum Zitat VA Centers of Excellence in Hepatitis C Research and Education. VA Treatment Recommendations for Patients with Chronic Hepatitis C: version 1.2. 2-25-1999 VA Centers of Excellence in Hepatitis C Research and Education. VA Treatment Recommendations for Patients with Chronic Hepatitis C: version 1.2. 2-25-1999
12.
Zurück zum Zitat Horiike N, Masumoto T, Nakanishi K et al (1995) Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10:246–249PubMed Horiike N, Masumoto T, Nakanishi K et al (1995) Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10:246–249PubMed
13.
Zurück zum Zitat Koyama R, Arase Y, Ikeda K et al (2006) Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 49:121–126PubMedCrossRef Koyama R, Arase Y, Ikeda K et al (2006) Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 49:121–126PubMedCrossRef
14.
Zurück zum Zitat Van Thiel DH, Friedlander L, Caraceni P, Molloy PJ, Kania RJ (1995) Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 50:M330–M333PubMed Van Thiel DH, Friedlander L, Caraceni P, Molloy PJ, Kania RJ (1995) Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol A Biol Sci Med Sci 50:M330–M333PubMed
15.
Zurück zum Zitat Thabut D, Le Calvez S, Thibault V et al (2006) Hepatitis C in 6,865 patients 65 year or older: a severe and neglected curable disease? Am J Gastroenterol 101:1260–1267PubMedCrossRef Thabut D, Le Calvez S, Thibault V et al (2006) Hepatitis C in 6,865 patients 65 year or older: a severe and neglected curable disease? Am J Gastroenterol 101:1260–1267PubMedCrossRef
16.
Zurück zum Zitat Nudo C, Gupta S, Alpert E et al Elderly patients are at greater risk for cytopenia during anitviral therapy for hepatitis C. CDDW 2004 abstract, accessed at: http://www.cagacg.org/cddw/cddw2004/abs/abs048.htm Nudo C, Gupta S, Alpert E et al Elderly patients are at greater risk for cytopenia during anitviral therapy for hepatitis C. CDDW 2004 abstract, accessed at: http://​www.​cagacg.​org/​cddw/​cddw2004/​abs/​abs048.​htm
17.
Zurück zum Zitat Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. Jama 285:2750–2756PubMedCrossRef Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. Jama 285:2750–2756PubMedCrossRef
Metadaten
Titel
Treatment Eligibility and Outcomes in Elderly Patients with Chronic Hepatitis C: Results from the VA HCV-001 Study
verfasst von
Judith I. Tsui
Sue Currie
Hui Shen
Edmund J. Bini
Norbert Brau
Teresa L. Wright
For the VA HCV-001 Study group
Publikationsdatum
01.03.2008
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2008
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9926-x

Weitere Artikel der Ausgabe 3/2008

Digestive Diseases and Sciences 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.